SPAC, reverse merger take Oak Hill, Scancell to NASDAQ

Argenx’s proposed takeout of Forte Biosciences for $2.2 billion was the week’s largest deal, as pharma buyers were largely on summer break and partnerships yielded no big-money transactions. The week also saw two biotechs pursue alternative paths to NASDAQ.

Oak Hill’s path to NASDAQ will involve a merger with a SPAC sponsored by RA Capital, a $45 million investment from the same firm, and a $55 million PIPE...